1. Home
  2. NEPH vs INKT Comparison

NEPH vs INKT Comparison

Compare NEPH & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$5.02

Market Cap

60.0M

Sector

Health Care

ML Signal

HOLD

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

HOLD

Current Price

$12.42

Market Cap

51.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEPH
INKT
Founded
1997
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.0M
51.7M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
NEPH
INKT
Price
$5.02
$12.42
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$6.00
$35.00
AVG Volume (30 Days)
74.6K
19.7K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$17,930,000.00
N/A
Revenue This Year
$33.32
N/A
Revenue Next Year
$12.27
N/A
P/E Ratio
$36.15
N/A
Revenue Growth
32.36
N/A
52 Week Low
$1.39
$4.56
52 Week High
$6.42
$76.00

Technical Indicators

Market Signals
Indicator
NEPH
INKT
Relative Strength Index (RSI) 48.33 51.40
Support Level $4.83 $11.48
Resistance Level $5.97 $13.34
Average True Range (ATR) 0.63 0.84
MACD -0.03 0.27
Stochastic Oscillator 28.93 67.49

Price Performance

Historical Comparison
NEPH
INKT

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Share on Social Networks: